Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design

WARRINGTON, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the trial design of its SEISMiC Phase 2b has been published by the European Society of Cardiology Heart Failure. The article is entitled, “Safety and efficacy of up to 60 hours of intravenous istaroxime in pre-cardiogenic shock patients: Design of the SEISMiC trial.” It can be found online in Wiley Online Library DIO: 10.1002/ehf2.15102. Results can be viewed at https://ir.windtreetx.com/corporate-presentation. The Heart Failure Society of America also shared the results.